<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Familial acute leukemia and myelodysplastic syndromes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Familial acute leukemia and myelodysplastic syndromes</h1>
<div class="graphic"><div class="figure"><div class="ttl">Familial acute leukemia and myelodysplastic syndromes</div><div class="cntnt"><table cellspacing="0"><colgroup span="9" width="11%"></colgroup> <tbody> <tr> <td class="subtitle1">Name of syndrome</td> <td class="subtitle1">Causative gene(s)</td> <td class="subtitle1">Pattern of inheritance</td> <td class="subtitle1">Characteristic hematologic malignancies</td> <td class="subtitle1">Other hematopoietic abnormalities</td> <td class="subtitle1">Susceptibility to other malignancies</td> <td class="subtitle1">Other organ systems affected</td> <td class="subtitle1">CLIA-approved testing available</td> <td class="subtitle1">Recommended diagnostic test</td> </tr> <tr class="divider_bottom"> <td>Familial AML with mutated <em>CEBPA</em> (<a href="https://www.omim.org/entry/116897" spellcheck="true" target="_blank">OMIM 116897</a>)</td> <td><em>CEBPA</em></td> <td>AD</td> <td>AML</td> <td>None</td> <td>None</td> <td>None</td> <td>Yes</td> <td><em>CEBPA</em> exon sequencing and gene rearrangement testing</td> </tr> <tr class="divider_bottom"> <td>Familial AML with mutated <em>DDX41</em></td> <td><em>DDX41</em></td> <td>AD</td> <td>MDS/AML, CMML </td> <td>Monocytosis</td> <td>Lymphoid malignancies Solid tumors (eg, colon, gastric, breast, pancreatic, bladder, melanoma) have also been reported but not yet definitively proven to be part of this syndrome.</td> <td>None </td> <td>Yes</td> <td><em>DDX41 </em>exon sequencing and gene rearrangement testing</td> </tr> <tr class="divider_bottom"> <td>Familial AML with mutated <em>MBD4</em></td> <td><em>MBD4</em></td> <td>AD </td> <td>AML </td> <td>None  </td> <td>Possible associations: Colon polyps and potentially colorectal cancer</td> <td>Colon polyps</td> <td>Yes</td> <td><em>MBD4</em> exon sequencing and gene rearrangement testing; may be suspected by the spectrum of tumor mutations.</td> </tr> <tr class="divider_bottom"> <td>Familial platelet disorder with propensity to myeloid malignancies (<a href="https://www.omim.org/entry/601399" spellcheck="true" target="_blank">OMIM 601399</a>)</td> <td><em>RUNX1</em></td> <td>AD</td> <td>MDS/AML/T cell ALL</td> <td>Thrombocytopenia (mild to moderate); bleeding propensity due to aspirin-like platelet dysfunction </td> <td>Eczema</td> <td>None</td> <td>Yes </td> <td><em>RUNX1</em> exon sequencing and gene rearrangement testing</td> </tr> <tr class="divider_bottom"> <td>Thrombocytopenia 2 (<a href="https://www.omim.org/entry/188000" spellcheck="true" target="_blank">OMIM 188000</a>)</td> <td><em>ANKRD26</em></td> <td>AD</td> <td>MDS/AML</td> <td>Thrombocytopenia (moderate); bleeding propensity due to platelet dysfunction</td> <td>None</td> <td>None</td> <td>Yes</td> <td>5'UTR and exon sequencing of <em>ANKRD26</em></td> </tr> <tr class="divider_bottom"> <td>Thrombocytopenia 5 (<a href="https://www.omim.org/entry/616216" spellcheck="true" target="_blank">OMIM 616216</a>) </td> <td><em>ETV</em>6</td> <td>AD</td> <td>MDS/AML, CMML, B cell ALL, multiple myeloma</td> <td>Thrombocytopenia (moderate); platelet dysfunction</td> <td>Unclear</td> <td>None</td> <td>Yes</td> <td><em>ETV6 </em>exon sequencing and gene rearrangement testing<em></em></td> </tr> <tr class="divider_bottom"> <td>Familial MDS/AML with mutated <em>GATA2</em> (<a href="https://www.omim.org/entry/137295" spellcheck="true" target="_blank">OMIM 137295</a>)</td> <td><em>GATA2</em></td> <td>AD</td> <td>MDS/AML/CMML</td> <td> <p>None</p> <p>or</p> Monocytopenia, NK cell, dendritic cell, B cell, and/or CD4+ T cell lymphopenia</td> <td>None</td> <td> <p>Sensorineural deafness, immunodeficiency, cutaneous warts. MonoMAC syndrome (eg, pulmonary alveolar proteinosis; monocytopenia, NK cell-, dendritic cell-, and B cell- lymphopenia; disseminated atypical mycobacterial, viral, fungal infections).</p> <p>Emberger Syndrome: (eg, primary lymphedema; low CD4/CD8 ratio; cutaneous warts; sensorineural deafness)</p> </td> <td>Yes</td> <td><em>GATA2</em> exon sequencing, intron 5 enhancer region sequencing, and gene rearrangement testing</td> </tr> <tr class="divider_bottom"> <td>Congenital <em>SAMD9/SAMD9L</em> mutations</td> <td><em>SAMD9</em> and <em>SAMD9L</em></td> <td>AD</td> <td>Monosomy 7 MDS/AML </td> <td>Transient monosomy 7 and pancytopenia </td> <td>None  </td> <td>Homozygous <em>SAMD9 </em>deletions are associated with normophosphatemic familial tumoral calcinosis. Heterozygous <em>SAMD9 </em>mutations are associated with MIRAGE syndrome: adrenal hypoplasia, growth retardation, genital abnormalities, and enteropathy. Heterozygous <em>SAMD9L </em>mutations are associated with ataxia.</td> <td>Yes</td> <td>Full gene sequencing of <em>SAMD9 </em>and <em>SAMD9L </em>and gene rearrangement testing for both genes. Note the possibility of loss of the germline allele along with monosomy 7; strongly consider use of a non-hematopoietic tissue for germline testing.</td> </tr> <tr class="divider_bottom"> <td>Familial aplastic anemia/MDS with <em>SRP72</em> mutation (<a href="https://omim.org/entry/602122" spellcheck="true" target="_blank">OMIM 602122</a>)</td> <td><em>SRP72</em></td> <td>AD</td> <td>MDS</td> <td>Aplastic anemia</td> <td>None</td> <td>Deafness</td> <td><strong>Yes</strong></td> <td><em>SRP72</em> exon sequencing and gene rearrangement testing</td> </tr> <tr class="divider_bottom"> <td>Myeloid neoplasms with germline predisposition due to 14q32 region duplications</td> <td>14q32 region duplications </td> <td>AD</td> <td>AML, MDS, ET, PV, PMF, CMML</td> <td>Myelofibrosis</td> <td>None</td> <td>None</td> <td>Yes</td> <td>SNP array or specially designed NGS assay</td> </tr> <tr class="divider_bottom"> <td>Telomere syndromes (TS) due to mutation in <em>TERC</em> (<a href="https://www.omim.org/entry/127550" spellcheck="true" target="_blank">OMIM 127550</a>) or <em>TERT</em> (<a href="https://www.omim.org/entry/187270" spellcheck="true" target="_blank">OMIM 187270</a>) or <em>RTEL1</em> (<a href="https://www.omim.org/entry/615190" spellcheck="true" target="_blank">OMIM 615190</a>)</td> <td><em>TERC/TERT</em></td> <td> <p>AD</p> AR (<em>TERT</em>)</td> <td>MDS/AML</td> <td>Macrocytosis; mild to moderate single or multiple cytopenias; aplastic anemia </td> <td>Squamous cell carcinomas of the head/neck and anogenital regions </td> <td> <p>Autosomal dominant TS (eg, idiopathic pulmonary fibrosis, idiopathic hepatic fibrosis).</p> <p>Autosomal recessive or X-linked recessive TS (eg, nail dystrophy, oral leukoplakia, skin hypo- or hyper-pigmentation, premature gray hair, dental caries, hepatic cirrhosis, pulmonary fibrosis)</p> <p>Severe forms may manifest cerebellar hypoplasia, immunodeficiency, and/or developmental delay</p> </td> <td>Yes</td> <td> <p>Full gene sequencing and large rearrangement testing of <em>TERT,</em> <em>TERC, RTEL1, </em>and other telomere associated genes</p> <p><em></em>Telomere length studies of lymphocyte subsets via flow FISH can also be performed to aid in diagnosis in conjunction with genetic testing and the clinical picture</p> </td> </tr> <tr class="divider_bottom"> <td><em>MECOM</em>-associated syndrome (<a href="https://www.omim.org/entry/165215" spellcheck="true" target="_blank">OMIM 165215</a> and <a href="https://www.omim.org/entry/616738" spellcheck="true" target="_blank">616738</a>) </td> <td><em>MECOM/EVI1</em> complex</td> <td>AD</td> <td>MDS</td> <td>Bone marrow failure/B cell deficiency </td> <td>None</td> <td>Radioulnar synostosis, clinodactyly, cardiac/renal malformations, presenile hearing loss</td> <td>Yes</td> <td><em>MECOM/EVI1</em> complex exon sequencing and genomic rearrangement testing</td> </tr> <tr class="divider_bottom"> <td>Familial ALL due to <em>TP53</em> mutation: rare Li Fraumeni syndrome presentation (<a href="https://www.omim.org/entry/151623" spellcheck="true" target="_blank">OMIM 151623</a>)</td> <td><em>TP53</em></td> <td>AD</td> <td>Familial ALL, especially hypodiploid</td> <td>None</td> <td>None</td> <td>Breast cancer, sarcomas, malignant brain tumors, adrenocortical carcinomas</td> <td>Yes</td> <td><em>TP53</em> exon sequencing and gene rearrangement testing</td> </tr> <tr class="divider_bottom"> <td>Familial B cell ALL due to <em>PAX5</em> mutation (<a href="https://www.omim.org/entry/615545" spellcheck="true" target="_blank">OMIM 615545</a>)</td> <td><em>PAX5</em></td> <td>AD</td> <td>Familial ALL, especially with ALL with 9p loss</td> <td>None</td> <td>None</td> <td>None</td> <td>Yes</td> <td><em>PAX5</em> exon sequencing and gene rearrangement testing</td> </tr> <tr class="divider_bottom"> <td>Germline <em>SH2B3</em> mutation (<a href="https://www.omim.org/entry/605093" spellcheck="true" target="_blank">OMIM 605093</a>)</td> <td><em>SH2B3</em></td> <td>AR</td> <td>Familial ALL</td> <td>None</td> <td>None</td> <td>Developmental delay, autoimmunity, chronic hepatitis</td> <td>Yes</td> <td><em>SH2B3</em> exon sequencing and gene rearrangement testing</td> </tr> <tr class="divider_bottom"> <td>Familial B cell ALL due to <em>IKZF1</em> mutation (<a href="https://www.omim.org/entry/613067" spellcheck="true" target="_blank">OMIM 613067</a> and <a href="https://www.omim.org/entry/603023" spellcheck="true" target="_blank">603023</a>) </td> <td><em>IKZF1</em> </td> <td>AD</td> <td>Familial ALL</td> <td>T cell, B cell, myeloid immunodeficiency </td> <td>None</td> <td>None</td> <td>Yes</td> <td><em>IKZF1</em> gene sequencing and gene rearrangement testing</td> </tr> </tbody></table></div><div class="graphic_footnotes">CLIA: Clinical Laboratory Improvement Amendments; AML: acute myeloid leukemia; MDS: myelodysplastic syndromes; AD: autosomal dominant; AR: autosomal recessive; CMML: chronic myelomonocytic leukemia; ALL: acute lymphoblastic leukemia; ET: essential thrombocytosis; CML: chronic myeloid leukemia; aCML: atypical chronic myeloid leukemia; SNP: single nucleotide polymorphism; FISH: fluorescence in situ hybridization.</div><div class="graphic_reference">Adapted from: West AH, Godley LA, Churpek JE. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Ann N Y Acad Sci 2014; 1310:111.</div><div id="graphicVersion">Graphic 97500 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
